Q3 2025 Krystal Biotech Inc Earnings Call Transcript
Key Points
- Krystal Biotech Inc (KRYS) reported a strong quarter with net base revenue of $97.8 million, marking sustained growth.
- The company successfully launched VYJUVEK in Germany, France, and Japan, expanding its global footprint.
- Gross margins were impressive at 96% for the quarter, benefiting from optimized manufacturing processes.
- The FDA approved an updated VYJUVEK label, expanding the eligible patient population and enhancing dosing flexibility.
- Krystal Biotech Inc (KRYS) achieved over 615 reimbursement approvals in the US, reflecting strong market penetration.
- The contribution from ex-US markets, such as Germany, is still modest and expected to grow steadily rather than rapidly.
- The optimized manufacturing process has not yet been approved for products sold outside the United States, potentially affecting future gross margins.
- There is no full-year revenue guidance for VYJUVEK for 2026 due to the complexity of multiple global launches.
- The company faces logistical challenges in expanding the breadth of prescribers in ex-US markets.
- Enrollment and site activation for clinical trials, such as those for NK and CF, are ongoing and may impact the timing of data readouts.
Thank you for standing by, and welcome to the Krystal Biotech third-quarter 2025 earnings call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development. Please begin.
Good morning and thank you all for joining today's call. Earlier today, we released our financial results for the third quarter of 2025. The press release is available on our website at www.crystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today.
Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Laurent Goux, Senior Vice President and General Manager for Europe, and Kate Romano, Chief Accounting Officer.
This conference call will and our responses to questions may contain forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
